Business briefs: Takeda, Stryker

Share this article:

Takeda scored an approvals hat-trick Friday with the FDA's Friday approval of the active ingredient alogliptin (AKA Nesina) as a stand-alone treatment for type 2 diabetes—as well as alogliptin-metformin combination Kazano and alogliptin-pioglitazone combo Oseni.

Stryker is solidifying its Asian footprint. The Michigan device maker announced this month that it is buying out Asia-based Trauson Holdings for $764 million in cash. The firms have been working together since 2007. “The acquisition of Trauson is a critical step toward broadening our presence in China and developing a value segment platform for the emerging markets,” Stryker President and CEO Kevin Lobo said in a statement. The announcement also noted that Trauson is a major competitor. The deal is expected to close by the end of the second quarter.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

FDA lifts OncoMed partial hold

The FDA froze the clinical trial of anti-Fzd7 vantictumab in July over concern about "bone-related adverse events."

Research links estrogen and binge eating

Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.